CGTP governs the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps including all
steps in recovery, donor screening, donor testing, processing, storage, labeling, packaging, and distribution.
https://www.aretezoe.com/
1. CGTP governs the methods used in,
and the facilities and controls used for,
the manufacture of HCT/Ps including all
steps in recovery, donor screening,
donor testing, processing, storage,
labeling, packaging, and distribution.
ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
CURRENT
GOOD
TISSUE
PRACTICE
21 CFR 1271: CGTP
https://www.aretezoe.com/ 102/29/2016
2. 21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
PERSONNEL:
Manufacturer must have
sufficient, competent and
appropriately trained
personnel to ensure
compliance.
ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
https://www.aretezoe.com/ 202/29/2016
3. 21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
PROCEDURES:
Procedures appropriate to meet
core CGTP requirements for all
manufacturing steps and design
these procedures to prevent
circumstances that increase the
risk of the introduction,
transmission, or spread of
communicable diseases
ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
https://www.aretezoe.com/ 302/29/2016
4. ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
QUALITY PROGRAMS
• Manufacturer must establish and maintain a
quality program
• Procedures must be reviewed, approved
and revised as appropriate.
• Procedures for receiving, investigating,
evaluating, and documenting core CGTP
requirements, including complains and
possible contaminations
• Provisions on risk assessment and
appropriate follow-up (recall, FDA reporting)
• CAPA, audits, re-audits, deviations from
procedure, monitoring systems
• Training and education
• Validated performance of computer
software
https://www.aretezoe.com/ 402/29/2016
10. ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
PROCESSING AND PROCESS CONTROLS
• Prevent contamination or cross-
contamination Do not pool cells or
tissue from different donors
• Representative in-process control and
testing Dura mater: validated process
to prevent CJD
• Any change to a process must be
verified or validated and approved
before implementation by a
responsible person.
• Changes have to be communicated
to staff.
https://www.aretezoe.com/ 1002/29/2016
12. ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
LABELLING
• Establish and maintain
procedures
• Ensure identification,
prevent mix-ups
• Verify accuracy, legibility
and integrity
• Donor eligibility
• Type of HCT/P
• Expiration date, storage
temperature
• Warnings if applicable
• Instructions for use
• Name and address of the
establishment
https://www.aretezoe.com/ 1202/29/2016
15. ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
RECEIPT, DISTRIBUTION
• Pre-distribution: HCT/P not available
for distribution must be shipped in
quarantine.
• Availability for distribution: release
criteria have been met, shipment
signed off
• Packaging and shipping: establish
appropriate shipping conditions
• Procedures: release criteria,
identification, audit trail for all
activities, quantity of HCT/P subject,
disposition of the HCT/P, and return to
inventory.
• Traceability: HCT/P must be traceable.
https://www.aretezoe.com/ 1502/29/2016
16. ENVIRONMENTFACILITIES
EQUIPMENT
SUPPLIES
REAGENTS
PROCESSRECOVERY
LABELLING STORAGE
DONORSDISTRIBUTION
21 CFR 1271: CGTP
CURRENT GOOD
TISSUE PRACTICE
RECORDS
• Maintain records of each step as
required
• Accurate, indelible, and legible,
identifiable and retrievable
• Identify Responsible Person
• Records management system
• Records must be retained for 10
years
• Contracts and agreements must
be kept.
https://www.aretezoe.com/ 1602/29/2016
19. ADVERSE REACTIONS
• Non-reproductive only
• Manufacturers must investigate and
follow-up any adverse reaction involving a
communicable disease related to an
HCT/P that it made available for
distribution.
• Adverse reactions are reportable to FDA if:
• fatal;
• life-threatening;
• result in permanent impairment or
permanent damage
• necessitate medical or surgical
intervention, including hospitalization.
Form FDA-3500A within 15 calendar days
(Guidance for industry)
21 CFR 1271: CGTP
REPORTING, IMPORT, INSPECTIONS
https://www.aretezoe.com/ 1902/29/2016
20. BIOLOGICAL PRODUCT
DEVIATION REPORT
Manufacturers must report
HCT/P deviations relating to the
core CGTP requirements within
45 days of discovery
21 CFR 1271: CGTP
REPORTING, IMPORT, INSPECTIONS
Form FDA-3486
Guidance for industry
https://www.aretezoe.com/ 2002/29/2016
21. 21 CFR 1271: CGTP
REPORTING, IMPORT, INSPECTIONS
INSPECTIONS
Establishment that manufactures HCT/Ps must permit the
FDA to inspect its facilities, equipment, finished and
unfinished materials, containers, processes, HCT/Ps,
procedures, labeling, records, files, and papers.
https://www.aretezoe.com/ 2102/29/2016
22. 21 CFR 1271: CGTP
REPORTING, IMPORT, INSPECTIONS
IMPORT
The importer must notify the FDA which the HCT/P is offering for
import
Exceptions include reproductive HCT/Ps of the PHSA and to
peripheral blood stem/progenitor cells regulated solely under
section 361.
https://www.aretezoe.com/ 2202/29/2016
23. 21 CFR 1271: CGTP
REPORTING, IMPORT, INSPECTIONS
RETENTION, RECALL, DESTRUCTION, CESSATION OF
MANUFACTURING
• written order that the HCT/P be recalled and/or destroyed
• take possession of and/or destroy the violative HCT/P
https://www.aretezoe.com/ 2302/29/2016